32.83

1.17% 0.38

After Hours: 32.83

Immunocore Holdings Plc Adr (IMCR)

Overview News Price History Option Chain Financials Discussions Forecast

Immunocore Holdings Plc Adr stock is traded at $32.83, with a volume of 203.07K. It is up +1.17% in the last 24 hours and up +0.09% over the past month. Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.

Previous Close:

$32.45

Open:

$32.77

24h Volume:

203.07K

Relative Volume:

0.58

Market Cap:

$1.65B

Revenue:

$345.60M

Net Income/Loss:

$-79.01M

P/E Ratio:

-25.60

EPS:

-1.2822

Net Cash Flow:

$-18.62M

1W Performance:

+1.26%

1M Performance:

+0.09%

6M Performance:

-28.71%

1Y Performance:

-31.59%

1-Day Range:

$32.04

$33.32

1-Week Range:

$31.66

$33.94

52-Week Range:

$29.72

$76.98

Immunocore Holdings Plc Adr Stock (IMCR) Company Profile

Name

Immunocore Holdings Plc Adr

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

01235 5430281

Address

90 PARK DRIVE, OXFORDSHIRE

Employee

497

Twitter

Next Earnings Date

2024-11-05

Latest SEC Filings

IMCR's Discussions on Twitter

Compare IMCR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IMCR Immunocore Holdings Plc Adr	32.83	1.65B	345.60M	-79.01M	-18.62M	-1.2822
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Immunocore Holdings Plc Adr Stock (IMCR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-11-24	Downgrade	Mizuho	Outperform → Neutral
Oct-24-24	Initiated	UBS	Sell
Oct-07-24	Downgrade	Guggenheim	Buy → Neutral
Apr-29-24	Initiated	Leerink Partners	Outperform
Nov-20-23	Resumed	JP Morgan	Overweight
Nov-02-23	Initiated	Cantor Fitzgerald	Overweight
Oct-31-23	Initiated	Robert W. Baird	Outperform
Sep-13-23	Upgrade	JP Morgan	Neutral → Overweight
Sep-13-23	Initiated	Needham	Buy
Aug-16-23	Initiated	CapitalOne	Overweight
Jul-17-23	Initiated	Canaccord Genuity	Hold
Mar-31-23	Initiated	Mizuho	Buy
Mar-30-23	Initiated	Guggenheim	Buy
Mar-24-23	Initiated	Bryan Garnier	Buy
Dec-16-22	Upgrade	Goldman	Neutral → Buy
Nov-30-22	Initiated	Barclays	Overweight
Sep-09-22	Initiated	Morgan Stanley	Overweight
Sep-08-22	Initiated	Ladenburg Thalmann	Buy
Aug-08-22	Initiated	Cowen	Outperform
Aug-02-22	Initiated	BTIG Research	Buy
Feb-08-22	Initiated	H.C. Wainwright	Buy
Oct-20-21	Initiated	Oppenheimer	Outperform
Mar-02-21	Initiated	Goldman	Neutral
Mar-02-21	Initiated	JP Morgan	Overweight
Mar-02-21	Initiated	Jefferies	Buy

View All

Immunocore Holdings Plc Adr Stock (IMCR) Latest News

Nov 26, 2024

Wall Street Analysts Predict an 112.56% Upside in Immunocore (IMCR): Here's What You Should Know - MSN

Nov 26, 2024

Immunocore's SWOT analysis: biotech stock faces pivotal moment amid PRAME data - Investing.com India

Nov 13, 2024

FATE Q3 Earnings Beat On Higher Revenues, Pipeline In Focus - Barchart

Nov 13, 2024

SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark - Barchart

Nov 13, 2024

Nov 12, 2024

Mirum's Q3 Earnings Beat Estimates, 2024 Revenue View Raised - Barchart

Nov 12, 2024

Nov 11, 2024

Mizuho downgrades Immunocore stock to Neutral, slashes PT to $38 from $72 - Investing.com

Nov 11, 2024

Rocket Pharmaceuticals' Q3 Earnings Beat, Pipeline In Focus - Barchart

Nov 11, 2024

Nov 09, 2024

Immunocore repays Pharmakon loan, ends agreement - Investing.com India

Nov 09, 2024

Nov 08, 2024

PBYI Beats Q3 Earnings & Revenue Estimates, Revises '24 View, Stock Up - Barchart

Nov 08, 2024

Nov 06, 2024

Immunocore Holdings earnings beat by $0.50, revenue topped estimates - Investing.com India

Nov 06, 2024

Oct 24, 2024

Immunocore shares maintain buy rating on HIV treatment potential - Investing.com

Oct 24, 2024

Oct 09, 2024

Immunocore Holdings PLC (IMCR) Q2 2024 Earnings Call Highlights: Strong US Growth and Strategic ... - Yahoo Finance

Oct 09, 2024

Oct 03, 2024

Immunocore stock hits 52-week low at $29.72 amid market challenges - Investing.com

Oct 03, 2024

Sep 30, 2024

Immunocore's SWOT analysis: biotech stock poised for growth amid clinical trials - Investing.com UK

Sep 30, 2024

Sep 24, 2024

Financial Fitness Check: Examining Immunocore Holdings plc ADR (IMCR)’s Key Ratios - The Dwinnex

Sep 24, 2024

Sep 23, 2024

Immunocore stock hits 52-week low at $32.07 amid market challenges - Investing.com

Sep 23, 2024

Sep 16, 2024

TD Cowen maintains Buy rating on Immunocore shares on ovarian cancer drug data - Investing.com India

Sep 16, 2024

Quarterly Metrics: Quick and Current Ratios for Immunocore Holdings plc ADR (IMCR) - The Dwinnex

Sep 16, 2024